Costs of Chemotherapy Regimens for Colorectal Cancer
Author Information
Author(s): Hale J P, Cohen D R, Maughan T S, Stephens R J
Primary Institution: University of Glamorgan
Hypothesis
What are the costs and consequences of different chemotherapy regimens in metastatic colorectal cancer?
Conclusion
The study found that the Lokich regimen offers the best value for money compared to de Gramont and raltitrexed, despite similar clinical benefits.
Supporting Evidence
- Mean total societal costs were highest for de Gramont (£5051), followed by raltitrexed (£2616) and Lokich (£2576).
- Statistically significant cost differences were found between de Gramont and both Lokich and raltitrexed.
- The study showed that raltitrexed had similar response rates but increased toxicity compared to de Gramont.
Takeaway
This study looked at how much different cancer treatments cost and found that one treatment is cheaper and just as effective as another.
Methodology
An economic sub-study was conducted alongside a multi-centre randomised trial comparing three chemotherapy regimens, assessing costs from a societal perspective over a 12-week period.
Potential Biases
Potential bias in patient selection and representativeness of the sub-sample compared to the overall trial population.
Limitations
The study was limited to a sub-sample of patients from six centres, which may affect the generalizability of the findings.
Participant Demographics
Patients with advanced metastatic colorectal carcinoma, aged 18 and older, from six of the 45 centres in the main trial.
Statistical Information
P-Value
P<0.01
Confidence Interval
95%CI £914–£4037
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website